IN8bio Shares Fall After Preclinical Data From Non-Signaling CAR Platform Targeting Cancer Cells

IN8bio Inc INAB announced the ability of its non-signaling gamma-delta CAR-T platform (nsCAR) to target leukemic cells while preserving healthy B cells selectively.
IN8bio's nsCAR platform uses the innate immune recognition of gamma-delta T cells to distinguish between tumor and healthy tissue, offering a targeted but potentially less toxic approach.
Also Read: With Over 400% Upside, This Cancer Stock Offers 'Attractive Entry Point To Long-Term Investors,' Analyst Says.
In a 48-hour in vitro cytotoxicity experiment, the nsCAR platform demonstrated a greater than 15x difference in killing between leukemic cells and healthy B cells (79.7% versus 5.2%) when both express the CD19 target antigen.
The nsCAR platform is also engineered to express the cytokine interleukin-15 (IL-15) to enhance cellular persistence and the ability to target and kill tumor cells over time.
The platform can potentially broaden CAR technology's utilization for previously "undruggable" solid and liquid tumor targets, the company said.
Price Action: INAB shares are down 12.77% at $1.57 on the last check Thursday.